Enrollment snafus

Designing trials is challenging enough, but training investigators and managing hospitals to properly conduct the studies adds another level of difficulty. Intrabiotics Pharmaceuticals Inc. learned that the hard way, resulting in at least a one-year delay in completion of its Phase III trial of Ramoplanin Oral for the prevention of vancomycin-resistant enterococci (VRE) infections in patients who are immunocompromised due to chemotherapy or bone

Read the full 642 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE